BORTEZOMIB HETERO bortezomib 3.5 mg powder for injection vial

Pajjiż: Awstralja

Lingwa: Ingliż

Sors: Department of Health (Therapeutic Goods Administration)

Ingredjent attiv:

bortezomib, Quantity: 3.5 mg

Disponibbli minn:

Hetero Australia Pty Ltd

Għamla farmaċewtika:

Injection, powder for

Kompożizzjoni:

Excipient Ingredients: mannitol

Rotta amministrattiva:

Intravenous Bolus, Subcutaneous

Unitajiet fil-pakkett:

1 vial

Tip ta 'preskrizzjoni:

(S4) Prescription Only Medicine

Indikazzjonijiet terapewtiċi:

BORTEZOMIB HETERO in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy. BORTEZOMIB HETERO as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. BORTEZOMIB HETERO is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease. BORTEZOMIB HETERO in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.

Sommarju tal-prodott:

Visual Identification: White to off-white cake or powder contained in a clear glass vial; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

L-istatus ta 'awtorizzazzjoni:

Registered

Data ta 'l-awtorizzazzjoni:

2021-08-05